Skip over global navigation links
U.S. Department of Health and Human Services

Medical countermeasures for emergencies

In the last fifteen years, the world has experienced the first influenza pandemic in 40 years, anthrax attacks, the re-emergence of cholera in the Western Hemisphere, the largest Ebola epidemic ever recorded, and the global dissemination of vector-borne viral diseases such as chikungunya and Zika.

ASPR is the only agency responsible for advanced stages of development and manufacturing to make emergency medical countermeasures – drugs, vaccines, diagnostics, and medical devices needed in emergencies – available to the public. We are working with our partners across government and industry to develop medical products that combat emerging infectious diseases like Ebola and Zika as well as chemical, biological, radiological and nuclear (CBRN) threats. 

ASPR has been uniquely successful in promoting the development and acquisition of medical countermeasures for CBRN threats, pandemic influenza, antibiotic resistant bacteria, and emerging infectious disease threats. Since 2007, 23 products supported by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) have been cleared, approved or licensed by FDA and 21 products have been developed and/or procured for the Strategic National Stockpile.

Antimicrobial Resistance Attacking BiothreatsPandemic Influenza A Coordinated Federal Response








  • This page last reviewed: December 13, 2016